IN TR O D U C TIO N
Prostate cancer (PCA) is the second leading cause of cancer death in men [1] . Fortunately, after curative radical prostatectomy, men with organ-confined dis ease have a survival rate that is equal to men without PCA [2] , High incidence and possibility for curative treatment are important prerequisites for a possible value of screening for PCA. Further conditions that have to be fulfilled for the application of a test in a screening population are tolerability, accuracy, and acceptable cost. An accurate blood test would meet these requirements. Papsidero et al. [3] were the first to report high serum concentrations of prostate-spe cific antigen (PSA) in patients with PCA. Since then, several studies have shown that the determination of serum PSA is more reliable to predict PCA than either transrectal ultrasound (TRUS) or digital rectal exam ination (DRE) alone [4] . The American Cancer Society mediate PSA range, Benson et al. [6] introduced PSA density (PSAD), representing PSA divided by gland volume. They advocated a cutoff level for PSAD of 0.15 in patients with PSA between 4.0-10.0 ng/ml. Several authors have raised objections against the use of this cutoff value [7, 8] . PSA velocity (PSAV), the change in serum PSA over time, was subsequently introduced by Carter et al. [9] . They found a PSAV <0.75 ng/ml/year to be indicative for the presence of PCA. Because of the high intrapatient variability in PSA measurements, the calculation of PSAV must be done using PSA measurements taken at least 1 year apart and with at least three separate measurements [10] . In summary, the clinical value of PSAD and PSAV in differentiating between BPH and PCA in the intermediate PSA range is disputed. Based on the observation that the aging prostate increases in size, resulting in a rise in PSA production [11] , Oesterling et al. [8] constructed age-specific reference ranges for PSA. Using a different reference range for each agedecade rather than regarding an upper limit of 4.0 ng/ml as normal for all ages, the accuracy of PSA could thus be enhanced. However, in a trial involving 6,630 men conducted by Catalona et al. [12] , no dif ference was found in accuracy using age-specific ref erence ranges for PSA.
FREE-TO-TOTAL PSA RATIO, A NEW PARAMETER
In serum, PSA forms complexes with al-antichymotrypsin (ACT) and several other protease inhibi tors. The total PSA (t-PSA) measured by PSA assays represents the product of reactivity with free PSA (f-PSA) and PSA complexed to ACT (ACT-PSA). The proportion of t-PSA that forms a complex with ACT appears to be higher in patients suffering from PCA. As a result, the f-PSA/t-PSA (F/T) ratio in PCA pa tients is lower than in BPH patients. The establish ment of a reference range of this new parameter in men with BPH and in men with PCA could give the practicing urologist a valuable new tool in the differ entiation of BPH from PCA in the intermediate PSA serum range (2-20 ng/ml). This review summarizes the literature about the clinical use of the F/T ratio of PSA.
PHYSIOLOGY OF PSA
Originally identified in seminal plasma in 1971 by Hara et al. [13] , PSA was first isolated from prostatic tissue by Wang et al. in 1979 [14] . PSA is also named human glandular kallikrein 3 (hK3) and shows a re stricted chymotrypsin-like specificity. It is produced only in the prostatic secretory epithelium. Secreted in the seminal plasma at concentrations in the range of 0.2-5.0 mg/ml [15] , it plays a role in the liquefaction of semen through hydrolysis of semenogelin [16] . In vitro, proteolytic active PSA slowly forms stable com plexes with several extracellular pro tease inhibitors [17] . In vivo, the release of active PSA in intercellular fluids or blood plasma also results in inactivation of enzymatic activity [18] , PSA occurs in serum in dif ferent forms: free PSA (f-PSA, MW (molecular weight) 30 kDa), PSA bound to alpha-2-macroglobulin (A2M-PSA), MW 780 kDa, and PSA bound to alpha-l-anti-chymotrypsin (ACT-PSA), MW 90 kDa (Fig. 1) . A2M and ACT are extracellular protease in hibitors, referred to as serpins. PSA molecules which form a complex with A2M are engulfed by this pro-^ tein, resulting in sterical shielding of all its epitopes. The lack of exposure of epitopes therefore prevents the detection of A2M-PSA by PSA assays. On the other hand, ACT does not cover all epitopes of the PSA molecule. Whereas A2M is the major binder of PSA when it reaches circulation [19] , in 1991 Lilja et al. [20] 
Metabolism of PSA
The metabolism of PSA is largely unknown, A pi lot study performed by Agha et al. [26] indicates that the main site of metabolism of PSA is in the liver. Clearance data from studies measuring serum PSA after radical prostatectomy indicate a two-compart ment model for f-PSA elimination, with an initial 50 van Iersel e t al. , who by using an anti-ACT-detecting an tibody developed an assay specific for ACT-PSA in serum (Fig. 2a) . They showed that the C/T ratio is higher in patients with PCA than in patients with BPH. This was confirmed by Wood et al. [28] , Christensson et al. [22] , and Stamey et al. [29] . Theoreti cally, the F/T ratio equals 1 minus the C/T ratio. This would indicate that measurement of the F/T ratio would give no additional information to the measure ment of the C/T ratio. However, assays of the ACT-PSA complex can severely overestimate the concen tration of ACT-PSA in serum because of nonspecific adherence of ACT or cathepsin-G complexed to ACT to the solid phase of the assay [30] , proportionally more so at lower concentrations of PSA. Instead of measuring ACT-PSA with an anti-ACT antibody, it is possible to selectively measure f-PSA using an anti body against an epitope which is obscured after com plex formation to ACT (Fig. 2b) . The accuracy of f-PSA assays in comparison with assays of the ACT-PSA complex suggest that better discrimination is ob tained by using the F/T instead of the C/T ratio [22, 30] .
The reason for the relatively low F/T PSA ratio in prostate cancer patients is unknown. ACT is pro- The response of such a t-PSA assay which is depen dent on the F/T ratio is called "skewed." This in con trast to a t-PSA assay with an equimolar response, in which the results are independent of the F/T ratio. The clinical implication of this finding is that when compared to the Hybritech assay, serum specimens measured with the IMx assay are less likely to exceed a certain cutoff value for t-PSA, and when they do, this will be more often due to a high F/T ratio. This is the case in benign conditions, resulting in the ten dency of an inferior diagnostic capacity to differenti ate BPH from PCA. Mean measured concentrations in identical serum samples may differ up to 36% be tween different t-PSA assays [36] . Interpreting t-PSA concentrations therefore requires awareness of the applied method and accurately determined reference ranges, Efforts to reach an international standard for measurements of PSA are currently being deter mined by Chen et al. [37] . Besides a careful selection of antibodies, a universal calibrator for the construc tion of the response curve, using a combination of 90% PSA-ACT complex with 10% f-PSA, is recom mended [36] .
FACTORS T H A T CAN BIAS MEASUREMENT OF F/T PSA RATIO Prostatic Manipulations
Many studies have been performed to investigate the effect of various manipulations of the prostate on t-PSA serum level. After cystoscopy, no significant change is seen in the serum t-PSA level [38] . After prostate biopsies and after transurethral resection of the prostate (TURP), the median serum t-PSA rises, respectively, to 7.9 ng/ml and 5.9 ng/ml [38] . The re sults of these studies do not necessarily have to be transferable to measurement of f-PSA and the F/T PSA ratio. Glenski et al. [39] showed that DRE does not influence serum t-PSA, whereas Collins et al. [40] , for instance, found a significant F/T ratio in crease of 0.16 after DRE. In this study, the F/T ratio rose 0.20 after biopsy, and no significant change was found after cystoscopy. Hershman et al. [41] de scribed a rise in F/T ratio after ejaculation. In view of the facts that in semen the ratio of f-PSA is much higher than in serum [15] and that the rise of t-PSA in men with prostatitis is caused by a disruption of the normal physiological barriers to PSA between ductal lumen and stroma in prostatic tissue [42] , a relatively higher rise in f-PSA after prostatic manipulations could be caused by leakage of f-PSA originating from the intraluminal compartment after trauma of the basal membrane.
Stability of PSA After Venesection
The stability in daily laboratory practice of the F/T ratio after venesection might be different from that of t-PSA. Woodrum et al. [43] reported a stable F/T ratio when serum was processed within 3 hr of venesec tion, and stored at a maximum of -20°C during a 6-month period, for at least five freeze-thaw cycles. Serum which was stored at 4°C or processed 8 hr after blood draw showed a significant decrease in f-PSA. selection of candidates for prostate biopsies in a screening population. In the study of Smith et aL [63] , approximately 40% of biopsies could have been
USE OF F /T RATIO IN DETECTION OF PROSTATE CANCER
U sing the F/T ratio, accuracy in the diagnosis of P C A can be enhanced [22] . In 422 randomly chosen m e n with no clinical signs of PCA, the lower limit of n o r m a l (95th percentile) of the F/T PSA ratio was f o u n d to be 0.15 [44] . This ratio was constant for men b e tw e e n age 40-79 years. In a study in which no restrictions w ere made on the basis of PSA levels, K l e e et al. [45] found that the area under the receivero p era tin g curve (AUC) for the F/T ratio was less than o r equal to the AUC for the total PSA for all age g r o u p s . 
F/T Ratio in the Intermediate t-PSA Range
A n overview of several studies performed on the capability of the F/T ratio to differentiate between B P H and PCA in the intermediate PSA range is given i n Table I . Compared to measurement of t-PSA only, m easu rem en t o f the F/T ratio in studies performed by v a n Iersel et al. [66] (Fig. 3) , Oesterling et al. [58] and S agalow sk y et al. [59] showed an increase of AUC of, resp ectively, 0*51 to 0.68, 0.53 to 0.73, and 0.52 to 0.72 f o r discrimination between BPH and PCA in the in term ediate t-PSA range. This means that in this PSA r a n g e , differentiation between BPH and PCA using t h e t-PSA values is not significantly better than by c h a n c e (AUC = 0.5), and that by using the F/T ratio, a fair improvement in this differentiation can be m a d e . Petteway et al, [62] measured the F/T for two different assays in the same group of patient sera. T h e y concluded that different ratios of F/T PSA are n ecessa ry to achieve comparable sensitivities. This m u s t be taken into consideration when extrapolating fin d in g s from one assay to another. As can be seen in T ab le I, a cutoff value for the F/T ratio in the range of 0 .1 7 -0 .2 5 gives a sensitivity of approximately 90%, w h ile a specificity of 20-45% is reached. Physician j u d gm en t m ust be involved in choosing F/T ratio cut o f f , since one must choose between increased cancer d etection rate (sensitivity) and increased biopsy rate (specificity), as evidenced in Table I . The final goal is t o determine if F/T ratio is an accurate test for the avoided while maintaining a 90% sensitivity for the presence of prostate cancer. The percentage of saved biopsies will vary among different studies according to the difference in prior probability of cancer inci dence. An alternative approach was brought forward by Flemming et al. [46] , who in a study on cost-effec tiveness of screening tests for prostate carcinoma found the cost per life-year saved when biopsying all screenees was equal when only biopsying according to the outcome of DRE and serum PSA. However, most men are probably even more reluctant to un dergo a routine prostate biopsy, as women are for having a cervical smear done. Consequently, the lack of tolerability to the screenees most likely will prevent this approach from gaining acceptance. *t~PSA, range of t-PSA in study; n, number of cases histopathologically proven as respectively PCA and BPH; cutoff, F/T ratio below which cases were destined as BPH and above which cases were destined as having PCA; re, retrospective; pr, prospective. Assays: 1, Centrocor; 2, AxSYM, Abbott; 3, Tandem-R, Hybritech; 4, Dianon; 5, free with DPC-Immulite and total with TOSOH; ni, not indicated. ' '"''Unpublished data.
F/T Ratio and Stage
Several studies have been performed to investigate whether the correlation of pathological stage with preoperative F/T ratio is superior to the correlation with t-PSA. In retrospective studies performed by Hendricks et al. [50] and Lerner et al. [51] , the F/T ratio was measured of 70 and 178 men, respectively, who underwent a radical prostatectomy. They con cluded that the PSA F/T ratio could not predict whether PCA has spread beyond the prostate gland at time of prostatectomy. Prospective studies carried out by Partin et al. [52] and Graefen et al. [53] in 288 and 53 men, respectively, brought the same result. In a study of 33 patients who underwent radical pros tatectomy as a result of a screening program, Ar cangeli et al. [54] found that F/T ratio <0.14 significantly correlated with a higher stage (P 0.05).
Regarding the limited number of cases included in the latter study, the outcome of the former studies suggests that F/T ratio provides no additional infor mation on the prediction of pathological stage for men with clinically localized prostate cancer. [54] found that F/T ratio <0.14 was significantly corre lated with a higher Gleason grade and high percentratio seems to facilitate the differential diagnosis of PCA and BPH in this t-PSA range, saving approxi mately 30% of unnecessary biopsies. In this respect an international standardization of t-PSA measure ments and of assays for the determination of F/T ratio would be most welcome. This would not only h elp the patients and physicians with a better differentia tion between BPH and PCA, but would also help th e manufacturers of PSA-assays in obtaining acceptance of the determination of F/T ratio for use in screening programs a g e of cancer (P 0.05). The use of the outcome of pathology on the basis o f performed biopsies as a gold standard is not per fect. As reported earlier by several groups, false-negative results and an underestimation of Gleason grade are common in the pathologic evaluation of biopsies. To further evaluate a possible relationship between tumor volume and Gleason grade, a study o n preoperative F/T PSA ratios must be performed in patients undergoing radical prostatectomy. No rela tionship between DNA ploidy and F/T ratio was ob served by Lerner et al. [51] .
PSA Expression in Cells in Peripheral Blood

R EFER EN C ES
CONCLUSIONS
The role of PSA in detecting early prostate cancer is undergoing extensive scrutiny. Because of the overlap in serum t-PSA in patients with BPH and PCA in the intermediate t-PSA range, any improve ment in accuracy of serum PSA measurements will
